INNMF
Price:
$0.059
Market Cap:
$32.50M
Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics L...[Read more]
Industry
Biotechnology
IPO Date
2021-01-08
Stock Exchange
PNK
Ticker
INNMF
According to Amplia Therapeutics Limited’s latest financial reports and current stock price. The company's current PE Ratio is -5.90. This represents a change of 71.45% compared to the average of -3.44 of the last 4 quarters.
The mean historical PE Ratio of Amplia Therapeutics Limited over the last ten years is -3.26. The current -5.90 PE Ratio has changed 17.98% with respect to the historical average. Over the past ten years (40 quarters), INNMF's PE Ratio was at its highest in in the March 2015 quarter at 0. The PE Ratio was at its lowest in in the September 2020 quarter at -7.74.
Average
-3.26
Median
-2.81
Minimum
-10.52
Maximum
-0.49
Discovering the peaks and valleys of Amplia Therapeutics Limited PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 638.88%
Maximum Annual PE Ratio = -0.49
Minimum Annual Increase = -81.27%
Minimum Annual PE Ratio = -10.52
Year | PE Ratio | Change |
---|---|---|
2024 | -3.41 | 12.99% |
2023 | -3.02 | -47.08% |
2022 | -5.71 | -45.74% |
2021 | -10.52 | 578.89% |
2020 | -1.55 | -56.78% |
2019 | -3.59 | 638.88% |
2018 | -0.49 | -81.27% |
2017 | -2.59 | 157.82% |
2016 | -1.00 | 33.72% |
2015 | -0.75 | 52.83% |
The current PE Ratio of Amplia Therapeutics Limited (INNMF) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-4.05
5-year avg
-4.84
10-year avg
-3.26
Amplia Therapeutics Limited’s PE Ratio is less than Fortress Biotech, Inc. (-0.62), less than Checkpoint Therapeutics, Inc. (-3.48), less than Avenue Therapeutics, Inc. (-0.23), less than Pieris Pharmaceuticals, Inc. (-1.39), less than Aileron Therapeutics, Inc. (-1.83),
Company | PE Ratio | Market cap |
---|---|---|
-0.62 | $44.44M | |
-3.48 | $180.50M | |
-0.23 | $3.84M | |
-1.39 | $22.15M | |
-1.83 | $53.51M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Amplia Therapeutics Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Amplia Therapeutics Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Amplia Therapeutics Limited's PE Ratio?
How is the PE Ratio calculated for Amplia Therapeutics Limited (INNMF)?
What is the highest PE Ratio for Amplia Therapeutics Limited (INNMF)?
What is the 3-year average PE Ratio for Amplia Therapeutics Limited (INNMF)?
What is the 5-year average PE Ratio for Amplia Therapeutics Limited (INNMF)?
How does the current PE Ratio for Amplia Therapeutics Limited (INNMF) compare to its historical average?